Anuncio • Mar 18
SynBiotic SE, Annual General Meeting, Apr 23, 2026 SynBiotic SE, Annual General Meeting, Apr 23, 2026, at 10:00 W. Europe Standard Time. Board Change • Mar 09
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Board Change • Feb 10
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Board Change • Jan 26
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Price Target Changed • Nov 27
Price target decreased by 45% to €6.50 Down from €11.80, the current price target is an average from 2 analysts. New target price is 224% above last closing price of €2.01. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €2.24 last year. Board Change • Nov 27
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Board Change • Sep 08
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Price Target Changed • Sep 08
Price target decreased by 28% to €11.80 Down from €16.30, the current price target is provided by 1 analyst. New target price is 297% above last closing price of €2.98. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.44 next year compared to a net loss per share of €2.24 last year. New Risk • Jul 01
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€24.5m market cap, or US$28.8m). Board Change • Jun 18
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Anuncio • Apr 19
SynBiotic SE announced that it expects to receive €2.4 million in funding SynBiotic SE announced a private placement that it will issue non-interest-bearing convertible bonds for the gross proceeds of up to €2,400,000 on April 17, 2025. The company will issue in several tranches of up to €200,000 each. The issue of the first convertible bonds is scheduled to start at the end of April 2025. New Risk • Apr 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Revenue is less than US$5m (€3.9m revenue, or US$4.4m). Market cap is less than US$100m (€21.2m market cap, or US$24.1m). Board Change • Mar 28
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Board Change • Feb 12
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Price Target Changed • Dec 27
Price target decreased by 24% to €12.45 Down from €16.30, the current price target is an average from 2 analysts. New target price is 183% above last closing price of €4.40. Stock is up 47% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year. Board Change • Dec 27
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Price Target Changed • Nov 20
Price target decreased by 24% to €12.45 Down from €16.30, the current price target is an average from 2 analysts. New target price is 123% above last closing price of €5.58. Stock is up 89% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year. Board Change • Nov 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of Advisory Board Bruce Linton was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Aug 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.9m free cash flow). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Revenue is less than US$5m (€4.1m revenue, or US$4.5m). Market cap is less than US$100m (€31.6m market cap, or US$35.1m). Anuncio • Aug 15
SynBiotic SE, Annual General Meeting, Sep 20, 2024 SynBiotic SE, Annual General Meeting, Sep 20, 2024, at 10:00 W. Europe Standard Time. New Risk • Aug 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€34.5m market cap, or US$37.9m). New Risk • Jul 01
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (€37.7m market cap, or US$40.4m). New Risk • Jun 21
New major risk - Revenue and earnings growth Revenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€35.6m market cap, or US$38.0m). New Risk • Mar 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (31% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€400k net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€35.8m market cap, or US$39.2m). Board Change • Oct 11
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Chairman of the Board of Directors Sebastian Stietzel is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. New Risk • Jul 02
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (€21.1m market cap, or US$23.0m). Breakeven Date Change • May 31
No longer forecast to breakeven The analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023. Price Target Changed • Apr 13
Price target increased by 28% to €75.00 Up from €58.50, the current price target is provided by 1 analyst. New target price is 859% above last closing price of €7.82. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €0.19 next year compared to a net loss per share of €4.15 last year. Anuncio • Nov 25
SynBiotic SE Appoints Bruce Linton as Chairman of Newly Created Advisory Board SynBiotic SE, accelerates implementation of the operational platform to achieve market leadership in the upcoming national legalization of recreational cannabis by securing Bruce Linton to its team. Mr. Linton is one of the most experienced and most successful cannabis entrepreneurs and investors globally and has been the driving force behind the creation of multiple global multi-billion dollar cannabis enterprises, several of them listed on NYSE, Nasdaq, TSX, TSX:V, CSE and ASX. Most notably, Mr. Linton is the founder and former Chairman and CEO of the global cannabis company Canopy Growth Corporation, which, at the time of his departure, had a market valuation of approximately CAD 20 billion and more than 25% market share in the Canadian recreational market while also being a global top tier supplier. Canopy was the first North American supplier to the German medical cannabis market. Combining unparalleled expertise in the areas of both medical and recreational cannabis, Mr. Linton is a powerful asset given SynBiotic's expansion plans, which cover both segments. Mr. Linton has been appointed as Chairman of SynBiotic's newly created Advisory Board and has invested capital in the company's most recent financing round. His investment plus options to buy further shares from existing shareholders will bring him to an ownership of approx. 5% in SynBiotic. Board Change • Nov 17
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Anuncio • Sep 02
SynBiotic SE Launches Full-Line Medical Cannabis Brand SynBiotic SE launches full-line medical cannabis brand. In mid-September, the pharmacy market is due to attend Expopharm, the most important leading European trade fair. SynBiotic SE will present its new brand Hempamed Rx at its own booth. Europe's largest listed corporate group in the hemp and cannabis sector is launching an extensive range of full-spectrum extracts, dronabinol and various flowers. In this process, canna.sales GmbH becomes SynBiotic Sales GmbH, with a fifteen-person field sales team consisting of employees with many years of experience in the field of medical cannabis, and GECA Pharma GmbH, responsible for the import and distribution of medical cannabis products, becomes SynBiotic Distribution GmbH. Sales offensive in the field of medical cannabis: While other cannabis companies are downsizing their sales teams and seemingly fully concentrate on the legalization of recreational use, are keeping a firm eye on all areas of the existing and future cannabis market," says Lars Müller, CEO of SynBiotic SE. The goal: to provide competent advice throughout Germany. With the sales offensive, the Munich-based corporate group wants to underline its clear vision in the wake of increasing treatments and prescriptions for medical cannabis. Products from this area can be used to treat chronic pain, among other things. In particular, patients suffering from depression and anxiety/sleep disorders, but also Tourette's, MS or epilepsy, can alleviate their symptoms and the resulting pain through the use of medical cannabis. Strong pipeline: Unprecedented product innovations: SynBiotic SE will build up further capacities in the important field of medical cannabis and further expand its dominant position not only on the distribution side. The launch of Hempamed Rx also culminates years of research and development of innovative products that will be launched under the new brand in the coming weeks and months. Particularly in the field of medical cannabis, it is important to enable treatments that are optimally adapted to individual complaints. The dosage forms in particular make an important contribution to this. In order to enable everyone to benefit from the advantages of medical cannabis, SynBiotic SE is constantly expanding its product portfolio through the use of various carrier substances. The high bio-availability is as much in focus as the good tolerability of the products. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Breakeven Date Change • Aug 27
Forecast to breakeven in 2022 The analyst covering SynBiotic expects the company to break even for the first time. New forecast suggests the company will make a profit of €1.70m in 2022. Average annual earnings growth of 93% is required to achieve expected profit on schedule. Is New 90 Day High Low • Jan 11
New 90-day high: €25.60 The company is up 51% from its price of €17.00 on 13 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period. Is New 90 Day High Low • Dec 03
New 90-day high: €20.20 The company is up 13% from its price of €17.90 on 04 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Is New 90 Day High Low • Nov 03
New 90-day low: €13.90 The company is down 15% from its price of €16.40 on 04 August 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. Is New 90 Day High Low • Oct 08
New 90-day low: €14.10 The company is down 21% from its price of €17.90 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 8.0% over the same period. Anuncio • Oct 08
SynBiotic SE (DUSE:L3D) acquired 25% stake in GreenLight Pharmaceuticals Ltd. SynBiotic SE (DUSE:L3D) acquired 25% stake in GreenLight Pharmaceuticals Ltd on October 6, 2020. In addition to the acquired share, SynBiotic also receives the option to strengthen its commitment in the future through further shares.
SynBiotic SE (DUSE:L3D) completed the acquisition of 25% stake in GreenLight Pharmaceuticals Ltd on October 6, 2020. Anuncio • Sep 22
SynBiotic SE (DUSE:L3D) entered into an agreement to acquire BioCBD E-commerce business of Umtr Group Limited SynBiotic SE (DUSE:L3D) entered into an agreement to acquire BioCBD E-commerce business of Umtr Group Limited on September 21, 2020. Under the terms of transaction, certain tangible and intangible assets as well as the Umtr Group's customer base relating to BioCBD e-commerce are to be taken over by SynBiotic SE. The purchase price is to be paid partly in cash and partly in cash or in shares and comprises a total of a low single-digit million amount. Major part of purchase price can be paid in exchange for shares of SynBiotic.